Cal Cohen

Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials

Kristine M. Erlandson, Christoph C Carter, Kathleen Melbourne et al. · Clinical Infectious Diseases · 2021 · 112 citations · Full text

Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen

Zoë Fox, Andrew Phillips, Cal Cohen et al. · AIDS · 2008 · 73 citations · Full text

Effect of Prolonged Discontinuation of Successful Antiretroviral Therapy on CD4⁺T Cell Decline in Human Immunodeficiency Virus–Infected Patients: Implications for Intermittent Therapeutic Strategies

Pablo Tebas, Keith Henry, Kristin Mondy et al. · The Journal of Infectious Diseases · 2002 · 50 citations · Full text

Intermittent Therapeutic Strategies, Immunology, Cd4 T Cell Responses +16

Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts

Dathan M. Byonanebye, Mark N. Polizzotto, Fernando Maltêz et al. · The Lancet HIV · 2024 · 41 citations · Full text

Respond Consortium Cohorts, Hypertension, Preventive Medicine +14

STAR Study: single tablet regimen emtricitabine/rilpivirine/tenofovir DF is non‐inferior to efavirenz/emtricitabine/tenofovir DF in ART‐naïve adults

Cal Cohen, DA Wohl, José Ramón Arribas et al. · Journal of the International AIDS Society · 2012 · 29 citations · Full text

Superior Efficacy, Fda Snapshot Algorithm, Single Tablet Regimen +13